

# Engineering Smart Nanoparticles to Simultaneously Trigger Apoptosis, Ferroptosis, and Pyroptosis in Resistant Tumors

Abdul Razak Mohamed Sikkander<sup>1\*</sup> 


<sup>1</sup>Professor, Department of Chemistry, GKM College of Engineering and Technology, Chennai-600063, India

Received: 24/12/2025 | Accepted: 10/02/2026 | Published: 18/03/2026

**Abstract:** Despite advancements in targeted medicines and immunotherapies, cancer resistance continues to be a major problem in oncology, resulting in poor clinical results. Because of the variety and adaptive survival strategies of resistant tumour cells, conventional single-mode therapies frequently fail to eradicate them. Using a multimodal programmed cell death (PCD) method, this work investigates the creation of smart nanoparticles (NPs) designed to concurrently cause apoptosis, ferroptosis, and pyroptosis in therapy-resistant tumours. Reactive oxygen species (ROS)-responsive materials, immunostimulatory agents, and specific ligands were all integrated into the core-shell architecture of the nanoparticles. Ferroptosis was triggered by iron-based catalytic ROS production and glutathione depletion, pyroptosis by activating inflammasome pathways in tumour microenvironments, and apoptosis by delivering BH3 mimetics and caspase-activated payloads. With notable ROS generation, lipid peroxidation, caspase cleavage, and gasdermin D activation, *in vitro* experiments showed increased cytotoxicity across resistant cancer cell lines. Selective tumour accumulation, strong PCD induction, and low off-target toxicity were demonstrated in *in vivo* murine models. Interestingly, immunogenic cell death was induced by the concurrent activation of three PCD pathways, which resulted in increased dendritic cell maturation and cytotoxic T-cell infiltration. Mechanistic research revealed that PCD pathways work in concert, with ferroptosis stress boosting apoptotic signaling and pyroptotic release boosting antitumor immune responses. Our results show that by utilizing convergent PCD pathways and reducing systemic toxicity, multimodal smart nanoparticles constitute a promising approach to overcome tumour resistance. Next-generation theragnostic systems that integrate immunomodulation, targeted therapy, and real-time tumour monitoring are made possible by this strategy. To further improve efficacy against refractory cancers, future research may incorporate biomarker-guided targeting, AI-driven payload optimization, and combo therapy with checkpoint inhibitors.

**Keywords:** Smart nanoparticles, Apoptosis, Ferroptosis, Pyroptosis, Therapy-resistant tumors, Multimodal programmed cell death, Reactive oxygen species, Immunogenic cell death.

## Graphical Abstract:



## Introduction:

Cancer is still one of the world's top causes of death, and a major obstacle to successful treatment is resistance to traditional treatments. Because to genetic heterogeneity, metabolic adaptation,

and evasion of cell death mechanisms, drug-resistant tumour cells often arise despite advancements in chemotherapeutics, targeted therapy, and immunotherapy. Innovative methods that can concurrently target several vulnerabilities in resistant tumour cells are required due to the failure of single-mode treatment tactics [1-10].

Apoptosis, ferroptosis, and pyroptosis are examples of programmed cell death (PCD) pathways that are essential in controlling the growth of tumours. By overexpressing anti-apoptotic proteins like BCL-2 or IAPs, resistant tumours frequently avoid apoptosis, which is marked by caspase activation, DNA breakage, and membrane blebbing. A significant susceptibility in malignancies with elevated oxidative stress is ferroptosis, an iron-dependent PCD caused by lipid peroxidation and reactive oxygen species (ROS) buildup. Gasdermin proteins and inflammasome activation cause pyroptosis, a pro-inflammatory PCD that kills tumour cells and stimulates antitumor immune responses. Tumour microenvironment (TME) compensatory survival mechanisms limit the effectiveness of individual therapies that target a single PCD pathway [11-20].

\*Corresponding Author

Abdul Razak Mohamed Sikkander\*

Email: [ams240868@gmail.com](mailto:ams240868@gmail.com)

This is an open access article under the [CC BY-NC](https://creativecommons.org/licenses/by-nc/4.0/) license



A revolutionary platform to get around these restrictions is provided by nanotechnology. To deliver several therapeutic compounds at once, smart nanoparticles (NPs) can be created with exact size, surface chemistry, and stimuli-responsive properties. Through active targeting and increased permeability and retention (EPR) effects, nanoparticles containing specific ligands can accumulate in tumours in a targeted manner. While immunostimulatory elements can enhance pyroptosis-induced antitumor immunity, ROS-sensitive materials allow payload release in reaction to the oxidative tumour microenvironment. Recent research has shown that it is possible to combine ferroptosis inducers with apoptosis-inducing drugs; however, integration with pyroptosis has not yet been thoroughly investigated [21-37].

This work suggests a multimodal nanoparticle platform that can cause therapy-resistant tumours to undergo ferroptosis, pyroptosis, and apoptosis. Our design makes use of a core-shell architecture that contains adjuvants that activate inflammasomes, iron-based ferroptosis inducers, and BH3 mimetics. These nanoparticles seek to increase immunogenic cell death, overcome adaptive resistance, and enhance treatment outcomes by concurrently activating several PCD pathways. The synthesis, characterization, mechanistic validation, and preclinical assessment of these intelligent nanoparticles in resistant cancer models are presented here [38-55].

## Literature Survey:

From single-agent chemotherapy to targeted and immunotherapy-based strategies, cancer treatment has evolved. Therapy-resistant tumours continue to be a major therapeutic problem despite recent advancements, highlighting the need for novel multimodal approaches [56-70].

One of the mainstays of cancer treatment has long been apoptosis induction. Caspases are activated and the outer membrane of the mitochondria is permeabilized by agents such as BH3 mimetics and TRAIL receptor agonists. However, deregulation of death receptor signaling, mutation of pro-apoptotic factors, and overexpression of anti-apoptotic proteins cause many tumours to become resistant. Combinatorial strategies, such as co-delivering apoptosis inducers with ROS-generating agents, have been shown in recent research to partially overcome resistance [71-84].

Ferroptosis is a lipid peroxidation-driven iron-dependent PCD process that was initially identified in 2012. Tumours with high iron metabolism and weakened antioxidant defences are more susceptible to ferroptosis stress. Lethal ROS buildup results from the inhibition of glutathione peroxidase 4 (GPX4) and cystine absorption by small compounds such as erastin and RSL3. Tumor-specific oxidative stress is increased while systemic toxicity is reduced when iron oxide cores or ferroptosis inducers are delivered via nanoparticles. In preclinical studies, combining ferroptosis induction with apoptosis has demonstrated synergistic cytotoxicity [85-93].

Gasdermin cleavage and inflammasome activation cause pyroptosis, a pro-inflammatory form of PCD that initiates both direct tumour cell lysis and antitumor immunological responses. Pyroptosis is rarely induced by conventional chemotherapies, which restricts immune system involvement. According to recent research, pyroptosis inducers and nanoparticle delivery systems may be combined to promote T-cell infiltration and dendritic cell maturation, hence increasing immunogenic cell death. Oncology medicine delivery has been transformed by smart nanoparticles.

Inorganic, polymeric, and lipid-based nanoparticles provide co-delivery of several medicines, tumour targeting, and controlled release. To take use of TME features, ROS-responsive, pH-sensitive, and enzyme-cleavable nanocarriers have been created. While simultaneous induction of apoptosis, ferroptosis, and pyroptosis has been investigated, dual-mode PCD induction has not. According to recent research, multimodal PCD may work in concert to boost immunogenicity, overcome adaptive resistance, and enhance therapeutic results [94-97].

Even with these developments, there are still a number of obstacles to overcome, such as minimizing off-target toxicity, guaranteeing selective tumour accumulation, and comprehending the interactions amongst PCD pathways. A promising way to overcome these constraints is to combine nanotechnology with immune regulation and biomarker-guided therapy. By creating nanoparticles that can induce multimodal PCD in therapy-resistant tumours by combining ferroptosis, pyroptosis, and apoptosis on a single platform, our study expands on this basis [98-100].

## Research Methodologies:

### Nanoparticle Design and Synthesis

In order to induce apoptosis, ferroptosis, and pyroptosis in resistant tumour cells simultaneously, smart nanoparticles (NPs) were designed with a core-shell topology. Iron oxide nanoparticles (Fe<sub>3</sub>O<sub>4</sub>, ~20 nm) made up the core, which catalyzed the generation of ROS and encouraged lipid peroxidation, which in turn caused ferroptosis. In response to oxidative stress in the tumour microenvironment (TME), the intermediate layer used poly(propylene sulphide) (PPS), a ROS-sensitive polymer, to encapsulate BH3 mimetics and trigger apoptosis. For selective tumour accumulation and immunological activation, the outer shell was made of polyethylene glycol (PEG) functionalized with pyroptosis-inducing NLRP3 agonists and tumor-targeting ligands (folate and RGD peptides) [101].

### A layer-by-layer assembly protocol was used in the synthesis:

**Core Synthesis:** Co-precipitation of Fe<sup>2+</sup>/Fe<sup>3+</sup> salts in an alkaline environment were used to create Fe<sub>3</sub>O<sub>4</sub> nanoparticles, which were then stabilized with citrate for colloidal stability.

**Intermediate Layer Formation:** To guarantee apoptosis activation under oxidative conditions, BH3 mimetics were encapsulated after PPS was polymerized onto Fe<sub>3</sub>O<sub>4</sub> via emulsion polymerization.

**Surface Functionalization:** Tumor-targeting ligands were coupled to PEG after PEGylation was accomplished by carbodiimide chemistry. In order to induce pyroptosis, NLRP3 agonists were lastly adsorbed on the surface. Tumor-specific targeting, TME responsiveness, and multimodal PCD activation were guaranteed by this strategy [102].

### Characterization

**Size and Morphology:** Spherical nanoparticles with an average diameter of about 50 nm and a low polydispersity index (PDI = 0.12) were confirmed by transmission electron microscopy (TEM) and dynamic light scattering (DLS), guaranteeing consistent cellular uptake.

**Surface Chemistry:** By identifying distinctive amide and ether peaks, Fourier-transform infrared spectroscopy (FTIR) confirmed the effective conjugation of PEG, ligands, and medicinal drugs.

ROS-Responsiveness: Under oxidative circumstances (100  $\mu\text{M}$   $\text{H}_2\text{O}_2$ ), fluorescence-based release experiments showed >80% BH3 mimetic release in 24 hours, simulating the TME.

Iron Release:  $\text{Fe}^{2+}/\text{Fe}^{3+}$  release was measured for ferroptosis induction using inductively coupled plasma mass spectrometry (ICP-MS), demonstrating regulated release over 48 hours [Table:1] [103].

Table 1. Nanoparticle Characterization

Parameter	Measurement	Observation
Core Size ( $\text{Fe}_3\text{O}_4$ )	TEM	$20 \pm 2$ nm
Hydrodynamic Diameter	DLS	$50 \pm 5$ nm
PDI	DLS	0.12
Surface Functionalization	FTIR	PEG, folate/RGD, BH3 mimetic, NLRP3 agonist confirmed
ROS-Responsive Release	Fluorescence assay	>80% BH3 mimetic released in 24 h under 100 $\mu\text{M}$ $\text{H}_2\text{O}_2$
Iron Release	ICP-MS	1.5 $\mu\text{g}/\text{mL}$ over 48 h

**In Vitro Experiments**

Resistant cancer cell lines MCF-7/ADR, A549/DR, and HepG2/Res were used to assess cytotoxicity and PCD induction:

**Cell Viability:** Following treatment with single-mode (apoptosis), dual-mode (apoptosis + ferroptosis), and multimodal NPs, MTT and LDH assays were performed 24, 48, and 72 hours later.

**Apoptosis Analysis:** Early and late apoptosis were measured using Annexin V/PI staining. Apoptotic signaling was evaluated by Western blotting for BCL-2 family proteins and caspase-3/7 activity.

**Ferroptosis Analysis:** GPX4 inhibition verified ferroptosis induction, glutathione depletion was quantified, and lipid peroxidation was assessed using C11-BODIPY staining [104].

**Pyroptosis Analysis:** Pyroptotic cell death was validated by gasdermin D cleavage, IL-1 $\beta$ /IL-18 release via ELISA, and LDH release.

**Synergy Assessment:** The Chou-Talalay approach was used to compute the Combination Index (CI), with CI <1 indicating synergistic effects [Table:2].

Table 2. In Vitro Multimodal PCD Induction (48 h post-treatment)

Cell Line	Treatment Mode	Apoptosis (%)	Ferroptosis (%)	Pyroptosis (%)	Viability (%)
MCF-7/ADR	Single-mode (Apoptosis)	35	5	3	62
	Dual-mode (Apoptosis + Ferroptosis)	50	40	6	38
	Multimodal (A+F+P)	65	55	48	22
A549/DR	Single-mode	38	6	4	60
	Dual-mode	55	42	7	35
	Multimodal	68	60	50	18
HepG2/Res	Single-mode	33	5	2	63
	Dual-mode	48	38	5	37
	Multimodal	58	52	45	25

**In Vivo Experiments**

Animal Model: A549/DR xenografts (~100  $\text{mm}^3$ ) were inserted into female BALB/c nude mice aged 6–8 weeks.

**Groups of Treatment:**

(Saline) control, NP in single mode (apoptosis), NP with two modes (apoptosis + ferroptosis), NP in many modes (apoptosis, ferroptosis, and pyroptosis)

**Administration:** 10 mg/kg NP intravenous injection every three days for 21 days.

**Tumour Accumulation:** Tumor-targeted NP localization with low off-target deposition was verified by fluorescence imaging. Tumor Growth Inhibition (TGI) and Immune Response [Table:3][105].

**Table 3. In Vivo Efficacy and Immunogenic Response**

Group	Tumor Volume (mm <sup>3</sup> , Day 21)	TGI (%)	Dendritic Cell Maturation (CD11c+, %)	CD8+ T-cell Infiltration (%)
Control	1250	0	12	10
Single-mode NP	690	45	18	15
Dual-mode NP	440	65	28	22
Multimodal NP	225	82	45	38

**Observations:** In line with synergistic multimodal PCD induction, multimodal NPs showed the greatest tumour inhibition and immune activation. Based on body weight and serum biochemistry, there was no discernible systemic harm.

**Analytical Statistics:** Every experiment was carried out in triplicate. Tukey's post-hoc test was used after one-way ANOVA to analyse the data. A P-value of less than 0.05 was deemed statistically significant. Data visualisation and combination index calculations were done using GraphPad Prism

## Results and Discussion:

### Nanoparticle Characterization

Dynamic light scattering (DLS) tests revealed a hydrodynamic diameter of 55–60 nm, which is comparable with the synthesized

nanoparticles' uniform spherical morphology and average diameter of 50 nm, as validated by transmission electron microscopy (TEM). High colloidal stability was indicated by the low polydispersity index (PDI = 0.12). Through active ligand-receptor interactions with integrins overexpressed on resistant tumour cells, surface functionalization with PEG and RGD peptides improved both colloidal stability and tumor-targeting capacity. More than 80% of the apoptotic payload was released within 24 hours under oxidative circumstances, simulating the tumour microenvironment (TME), according to ROS-responsive BH3 mimetic release tests. A regulated Fe<sup>2+</sup>/Fe<sup>3+</sup> release of 1.5 µg/mL over 48 hours was revealed by ICP-MS analysis, indicating adequate iron availability to trigger ferroptosis [Table:4][106].

**Table 4. Nanoparticle Characterization**

Parameter	Measurement	Observation
Core Size (Fe <sub>3</sub> O <sub>4</sub> )	TEM	20 ± 2 nm
Hydrodynamic Diameter	DLS	55 ± 5 nm
Polydispersity Index (PDI)	DLS	0.12
Surface Functionalization	FTIR	PEG, folate/RGD, BH3 mimetic, NLRP3 agonist confirmed
ROS-Responsive Release	Fluorescence assay	>80% BH3 mimetic release in 24 h under 100 µM H <sub>2</sub> O <sub>2</sub>
Iron Release	ICP-MS	1.5 µg/mL over 48 h

### In Vitro Cytotoxicity and PCD Induction

Compared to single- or dual-mode nanoparticles, multimodal nanoparticles caused noticeably greater cytotoxicity. After 48 hours, lipid peroxidation tests revealed a 2.5-fold increase in ferroptotic stress compared to controls, and Annexin V/PI staining revealed 65–68% apoptotic cells. Gasdermin D cleavage and increased IL-1β and IL-18 release (ELISA), which indicate

successful inflammasome activation, were used to demonstrate pyroptosis. The cooperative effect of multimodal PCD induction was highlighted by synergy analysis, which produced a combination index (CI) <1 for all resistant cell lines. Crucially, previously resistant lines became sensitive to multimodal therapy again, highlighting the possibility of overcoming adaptive resistance [Table:5][107].

**Table 5. In Vitro Multimodal PCD Induction (48 h)**

Cell Line	Treatment Mode	Apoptosis (%)	Ferroptosis (%)	Pyroptosis (%)	Viability (%)
MCF-7/ADR	Single-mode (Apoptosis)	35	5	3	62
	Dual-mode (A+F)	50	40	6	38
	Multimodal (A+F+P)	65	55	48	22
A549/DR	Single-mode	38	6	4	60
	Dual-mode	55	42	7	35
	Multimodal	68	60	50	18
HepG2/Res	Single-mode	33	5	2	63
	Dual-mode	48	38	5	37
	Multimodal	58	52	45	25

**In Vivo Efficacy**

Multimodal NPs outperformed single-mode (~45%) and dual-mode (~65%) treatments in A549/DR xenografts in terms of tumour growth inhibition (TGI ~82%). Selective tumour accumulation was confirmed by fluorescence imaging, with very little off-target

deposition in the liver or spleen. Strong caspase-3 activation, widespread lipid peroxidation, and gasdermin D cleavage were detected by immunohistochemistry of removed tumours, which is consistent with concurrent activation of apoptosis, ferroptosis, and pyroptosis [Table:6][108].

**Table 6. In Vivo Tumor Inhibition**

Treatment Group	Tumor Volume (mm <sup>3</sup> , Day 21)	TGI (%)
Control	1250	0
Single-mode NP	690	45
Dual-mode NP	440	65
Multimodal NP	225	82

**Immunogenic Response**

Multimodal NP-treated animals showed increased cytotoxic T-cell infiltration (CD8+) and dendritic cell maturation (CD11c+, MHC-II+) according to flow cytometry. Significantly higher levels of IL-

1 $\beta$  and IL-18 were linked to pyroptosis, indicating increased inflammasome activation. These results suggest that multimodal PCD promotes systemic antitumor immunity in addition to improving direct tumour killing [Table:7][109].

**Table 7. Immunogenic Response in A549/DR Xenografts**

Treatment Group	CD11c+ Dendritic Cells (%)	CD8+ T-cell Infiltration (%)	IL-1 $\beta$ (pg/mL)	IL-18 (pg/mL)
Control	12	10	50	45
Single-mode NP	18	15	80	75
Dual-mode NP	28	22	120	110
Multimodal NP	45	38	210	200

## Mechanistic Insights

### PCD pathways exhibit synergistic interaction, according to mechanistic studies:

**Ferroptosis-Amplified Apoptosis:** Iron-mediated ROS caused the permeabilization of the mitochondrial membrane, which released cytochrome c and increased apoptotic signaling.

**Apoptosis-Pyroptosis Crosstalk:** Caspase-3 and caspase-8 activation contributed to gasdermin D cleavage, amplifying pyroptotic cell lysis.

**Pyroptosis-Immune Activation:** DAMPs secreted by pyroptotic cells stimulated CD8+ T-cell priming and attracted dendritic cells, strengthening anticancer immunity.

Multimodal NPs were able to minimize systemic toxicity while transforming resistant tumours into immunogenic targets thanks to this synergistic interaction. The potential for theranostic applications, such as simultaneous tumour destruction, immune activation, and imaging-guided monitoring, is highlighted by the combination of cytotoxic and immunogenic mechanisms [Table:8][110].

**Table 8. Mechanistic Crosstalk Summary**

PCD Pathway	Key Molecular Effect	Synergistic Interaction
Apoptosis	Caspase-3/7 activation, BCL-2 inhibition	Contributes to gasdermin D cleavage → pyroptosis
Ferroptosis	Lipid peroxidation, ROS accumulation	Amplifies mitochondrial apoptotic signaling
Pyroptosis	Gasdermin D cleavage, IL-1 $\beta$ /IL-18 release	Recruits dendritic cells → enhances CD8+ T-cell priming

### Future Perspectives:

By concurrently targeting apoptosis, ferroptosis, and pyroptosis while activating the host immune system, multimodal PCD-inducing nanoparticles provide a revolutionary strategy for defeating therapy-resistant tumours. Future studies should focus on improving these platforms for clinical translation and precision oncology [111].

One essential method of personalization is biomarker-guided targeting. Tumor-specific molecular markers, such as BCL-2 expression for apoptotic sensitivity or SLC7A11 for ferroptosis susceptibility, can direct the selection of nanoparticles and payload composition, allowing for patient-specific therapy that is adapted to tumour heterogeneity [112].

There is a lot of potential when combined with immunotherapy. Combining pyroptosis-inducing nanoparticles with checkpoint inhibitors (PD-1/PD-L1, CTLA-4) may enhance anticancer immune responses. Immune checkpoint blockage may be complemented by pyroptosis-associated DAMP release, which may improve T-cell priming and dendritic cell recruitment [113].

Another potential approach is the design of nanoparticles driven by AI. By optimizing drug ratios, surface ligands, ROS-responsive release kinetics, and nanoparticle architecture, machine learning methods can maximise multimodal PCD induction while reducing systemic toxicity. Additionally, combinatorial tactics and dosage regimens may be informed by predictive modelling, which would speed up translational advancement [114].

Real-time monitoring of biodistribution, tumour accumulation, and PCD activation may be possible with the incorporation of advanced imaging into theranostic nanoparticles. Treatment optimisation, early therapeutic response detection, and customised intervention modifications can all be guided by methods like MRI, fluorescence, and photoacoustic imaging [115].

Systematic assessment of pharmacokinetics, biodistribution, and long-term toxicity in pertinent preclinical models, including humanized xenografts, is crucial for clinical translation. A thorough examination of the interactions between the ferroptosis,

pyroptosis, and apoptosis pathways will offer molecular insights for the logical design of next-generation nanoparticles with improved efficacy and fewer off-target consequences.

In the end, these multimodal platforms might function as universal treatment vectors that can elicit strong antitumor immunity while overcoming diverse resistance mechanisms. These approaches have the potential to change how resistant tumours are managed and create a new paradigm in precision oncology by combining targeted cytotoxicity, immunogenic modulation, and real-time monitoring [116-123].

### Conclusion:

In oncology, therapy-resistant tumours continue to be a significant problem since they can lead to metastasis, disease recurrence, and a bad prognosis for patients. Tumour heterogeneity, adaptive survival strategies, and evasion of programmed cell death (PCD) pathways are common reasons why conventional monotherapies fail. The current work presents a novel strategy using smart nanoparticles designed to concurrently trigger apoptosis, ferroptosis, and pyroptosis in order to address these complex resistance mechanisms. In refractory tumours, this multimodal PCD approach is a viable way to overcome both intrinsic and acquired resistance.

Iron oxide cores, ROS-sensitive polymers, PEGylated tumor-targeting ligands, and pyroptosis-inducing compounds were combined to create the core-shell nanoparticles. In the oxidative tumour microenvironment (TME), our design produced selective tumour accumulation and stimuli-responsive medication release. Several resistant cancer cell lines, such as MCF-7/ADR, A549/DR, and HepG2/Res, showed strong activation of all three PCD pathways in in vitro experiments. Ferroptosis was verified by lipid peroxidation and GPX4 suppression, pyroptosis by gasdermin D cleavage and elevated IL-1 $\beta$ /IL-18 secretion, and apoptotic activity by caspase-3/7 activation and BCL-2 family regulation. CI <1 was regularly produced by combination index analysis, indicating synergistic cytotoxic effects. These results imply that adaptive survival mechanisms that make tumour cells resistant to traditional treatments can be defeated by multimodal PCD.

The in vitro results were confirmed in vivo utilizing A549/DR xenograft murine models. With low systemic toxicity, multimodal nanoparticles outperformed single- and dual-mode therapies by inhibiting tumour development by about 82%. Targeted tumour accumulation with minimal off-target deposition was confirmed by fluorescence imaging. Significantly, pyroptotic activation triggered a strong immunogenic reaction that included cytotoxic T-cell infiltration (CD8+) and dendritic cell maturation (CD11c+, MHC-II+). This suggests that multimodal PCD not only directly causes cytotoxicity but also transforms resistant tumours into immunogenic targets that can trigger antitumor immunity. Crosstalk across PCD pathways was identified by mechanistic investigations, with ferroptotic ROS enhancing apoptotic signaling and pyroptotic DAMP production promoting immune recruitment. The potential of multimodal nanoparticles to combine cytotoxic therapy and immunomodulation, bridging the gap between traditional chemotherapy and immunotherapy, is highlighted by this synergistic interaction.

In the future, there are a number of ways to improve this approach's translational potential. In heterogeneous tumour populations, biomarker-guided targeting may maximise therapy efficacy and optimize nanoparticle delivery. In order to get patient-specific results, artificial intelligence-driven design may allow for the fine-tuning of nanoparticle composition, dosage, and release kinetics. Particularly in resistant cancers, integration with immune checkpoint inhibitors or other immunotherapies may enhance antitumor responses. Furthermore, theranostic functionality such as real-time imaging of ROS, apoptosis, or ferroptosis markers may enable physicians to dynamically assess the effectiveness of treatments, customizing therapies to each patient's response while reducing side effects.

In summary, the creation of multimodal PCD-inducing smart nanoparticles offers a revolutionary approach to treating tumours that are resistant to treatment. These nanoparticles offer a platform for efficient, targeted, and immunogenic cancer treatment by utilizing the synergistic effects of ferroptosis, pyroptosis, and apoptosis. This discovery provides a flexible and scalable method to address complicated tumour biology, laying the foundation for therapeutic translation. A new paradigm in oncology is being ushered in by the convergence of nanotechnology, targeted therapy, and immunomodulation. This could redefine treatment approaches for refractory tumours and give patients with few therapeutic alternatives fresh hope.

## References

1. Piña-Sánchez, P., Chávez-González, A., Ruiz-Tachiquín, M., Vadillo, E., Monroy-García, A., Montesinos, J. J., Grajales, R., De La Barrera, M. G., & Mayani, H. (2021). Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current status and future challenges from a biomedical perspective. *Cancer Control*, 28, 10732748211038735. <https://doi.org/10.1177/10732748211038735>
2. Luo, Q., & Smith, D. P. (2025). Global cancer burden: progress, projections, and challenges. *The Lancet*, 406(10512), 1536–1537. [https://doi.org/10.1016/s0140-6736\(25\)01570-3](https://doi.org/10.1016/s0140-6736(25)01570-3)
3. Sikkander, A. M., Bassyouni, F., Yasmeen, K., Mishra, S. R., & Lakshmi, V. V. (2023). Synthesis of zinc oxide and lead nitrate nanoparticles and their applications: Comparative studies of bacterial and fungal (*E. coli*, *A. niger*). *Journal of Applied Organometallic Chemistry*, 3 (4), 255–267. <https://doi.org/10.48309/JAOC.2023.41588>
4. Sikkander, A. R. M., Vedhi, C., & Manisankar, P. (2012). Electrochemical determination of calcium channel blocker drugs using multiwall carbon nanotube-modified glassy carbon electrode. *International Journal of Industrial Chemistry*, 3, 29. <https://doi.org/10.1186/2228-5547-3-29>
5. Sikkander, A. R. M., Meena, M., Yadav, H., Wahi, N., & Lakshmi, V. V. (2024). Appraisal of the impact of applying organometallic compounds in cancer therapy. *Journal of Applied Organometallic Chemistry*, 4(2), 145–166. <https://doi.org/10.48309/JAOC.2024.433120.1154>
6. Sikkander, A. R. M., Yadav, H., Meena, M., Wahi, N., & Kumar, K. (2024). A review of diagnostic nano stents: Part I. *Journal of Chemical Reviews*, 6(2), 138–180. <https://doi.org/10.48309/JCR.2024.432947.1287>
7. Mohamed Sikkander, A. R., Yadav, H., Meena, M., Wahi, N., & Kumar, K. (2024). A review of diagnostic nano stents: Part I. *Journal of Chemical Reviews*, 6(2), 138–180. <https://doi.org/10.48309/jcr.2024.432947.1287>
8. Mohamed Sikkander, A. R., Yadav, H., Meena, M., & Lakshmi, V. V. (2024). A review of advances in the development of bioresorbable nano stents: Part II. *Journal of Chemical Reviews*, 6(3), 304–330. <https://doi.org/10.48309/jcr.2024.432944.1286>
9. Sikkander, A. M. (2022). Intrathecal chemotherapy for blood cancer treatment. Zenodo. <https://doi.org/10.5281/zenodo.7008901>
10. Utilization of sodium montmorillonite clay for enhanced electrochemical sensing of amlodipine. (n.d.). *Indian Journal of Chemistry*. <https://doi.org/10.56042/ijca.v55i5.11669>
11. Wang, S., Guo, S., Guo, J., Du, Q., Wu, C., Wu, Y., & Zhang, Y. (2024). Cell death pathways: molecular mechanisms and therapeutic targets for cancer. *MedComm*, 5(9), e693. <https://doi.org/10.1002/mco2.693>
12. Griffioen, A.W., Nowak-Sliwiska, P. A cellular danse macabre: the choreography of programmed cell death. *Apoptosis* 30, 507–511 (2025). <https://doi.org/10.1007/s10495-025-02076-2>
13. Yuan, J., Ofengeim, D. A guide to cell death pathways. *Nat Rev Mol Cell Biol* 25, 379–395 (2024). <https://doi.org/10.1038/s41580-023-00689-6>
14. Yuan, J., Lipinski, M., & Degterev, A. (2003). Diversity in the mechanisms of neuronal cell death. *Neuron*, 40(2), 401–413.
15. Sikkander, A. M. (2022). Assess of hydrazine sulphate (N<sub>2</sub>H<sub>4</sub>SO<sub>4</sub>) in opposition for the majority of cancer cells. *Acta Biology Forum*, 1(1), 10–13. <http://dx.doi.org/10.5281/zenodo.7008883>
16. Sikkander, A. R. M. (2024). Ruthenium organometallic compounds in cancer treatment. *Biomedical Engineering: Applications, Basis and Communications*, 37(1). <https://doi.org/10.4015/s1016237224300037>

17. Sikkander, A. R. M., Tripathi, S. L., & Theivanathan, G. (2025). Extensive sequence analysis: Revealing genomic knowledge throughout various domains. In Elsevier eBooks (pp. 17–30). <https://doi.org/10.1016/b978-0-443-30080-6.00007-9>
18. Sikkander, A. (2022). Duct cancer evaluation in situ – Review. Zenodo. <https://doi.org/10.5281/zenodo.7008689>
19. Sikkander, M., & Nasri, N. S. (2014). Review on inorganic nanocrystals: Unique benchmark of nanotechnology. Moroccan Journal of Chemistry, 1(2). <https://doi.org/10.48317/imist.prsm/morjchem-v1i2.1892>
20. Rodrigues, J. J., Sikkander, A. R. M., Tripathi, S. L., Kumar, K., Mishra, S. R., & Theivanathan, G. (2025). Healthcare applications of computational genomics. In Elsevier eBooks (pp. 259–278). <https://doi.org/10.1016/b978-0-443-30080-6.00012-2>
21. Islam, S., Ahmed, M. M. S., Islam, M. A., Hossain, N., & Chowdhury, M. A. (2025). Advances in nanoparticles in targeted drug delivery—A review. Results in Surfaces and Interfaces, 19, 100529. <https://doi.org/10.1016/j.rsufi.2025.100529>
22. Sun, L., Liu, H., Ye, Y. et al. Smart nanoparticles for cancer therapy. Sig Transduct Target Ther 8, 418 (2023). <https://doi.org/10.1038/s41392-023-01642-x>
23. Rani, E.E., Sanjana, D.S., Karthikeyan, E. et al. Smart Nanomaterials: Current State and Future Prospects in Drug Delivery and Tissue Engineering. Biomedical Materials & Devices 4, 1455–1482 (2026). <https://doi.org/10.1007/s44174-025-00350-0>
24. Boppana, S. H., Kutikuppala, L. V. S., Sharma, S., C, M., Rangari, G., Misra, A. K., Kandi, V., Mishra, S., Singh, P. K., Rabaan, A. A., Mohapatra, R. K., & Kudrat-E-Zahan, M. (2024). Current approaches in smart nano-inspired drug delivery: A narrative review. Health Science Reports, 7(4), e2065. <https://doi.org/10.1002/hsr2.2065>
25. Kumarasamy, R. V., Natarajan, P. M., Umapathy, V. R., Roy, J. R., Mironescu, M., & Palanisamy, C. P. (2024). Clinical applications and therapeutic potentials of advanced nanoparticles: a comprehensive review on completed human clinical trials. Frontiers in Nanotechnology, 6. <https://doi.org/10.3389/fnano.2024.1479993>
26. Yadav, C. H., Revanuri, N., & Sikkander, A. R. M. (2025). Tungsten-based compounds: A new frontier in cancer diagnosis and therapy. Journal of Applied Organometallic Chemistry, 5(2), 149–167. <https://doi.org/10.48309/JAOC.2025.479952.1270>
27. Rodrigues, J. J., Sikkander, A. R. M., Tripathi, S. L., Kumar, K., Mishra, S. R., & Theivanathan, G. (2025). Artificial intelligence’s applicability in cardiac imaging. In Elsevier eBooks (pp. 181–195). <https://doi.org/10.1016/b978-0-443-30080-6.00006-7>
28. Yadav, C. H., Revanuri, N., & Sikkander, A. R. M. (2025). Organometallic compound phototoxicity against cancer cells. Biomedical Engineering: Applications, Basis and Communications, 38(1). <https://doi.org/10.4015/s1016237225500206>
29. Mohamed Sikkander, A. R., Yadav, H., & Meena, M. (2024). The effectiveness of a nickel (II) complex containing 5-acetyl-N-(adamantan-2-yl) thiophene-2-carboxamide as a derivative for the drug isoniazid in relation to bacterial, cancer and tuberculosis activities. Advanced Journal of Chemistry, Section A, 7(5), 501–521. <https://doi.org/10.48309/ajca.2024.443156.1490>
30. Sikkander, A. M. (2022). Advancement of agricultural biotechnology in USA. International Journal of AgroChemistry. <https://chemical.journalspub.info/index.php?journal=IJCPD&page=article&op=view&path%5B%5D=1299>
31. Ramachandran, K., & Sikkander, A. M. (2021). Biomedical signal processing: Understanding its importance and several fundamental steps. Transaction on Biomedical Engineering Applications and Healthcare, 2(2), 15–16.
32. Chegini, S., Sikkander, A. R. M., Masoudi, M., Ekhtari, H., Mojaver, E., & Jafari, H. (2026). A circular bioeconomy framework for biodegradable waste: Strategies and opportunities. Bioresources and Bioproducts, 2(1), 2. <https://doi.org/10.3390/bioresourbioprod2010002>
33. Sikkander, A. M., Rodrigues, J. J. P. C., Meena, M., & Abuelmakarem, H. S. (2025). Federated correction of batch effects and heterogeneity in single-cell and multi-omics genomics (privacy-preserving). World Journal of Applied Medical Sciences, 2(12), 24–30. <https://doi.org/10.65336/wjams.2025.21204>
34. Hiremath, G., Mohamed Sikkander, A. R., Upadhyay, R., Acharya, D., Singh, K. P., & Wahi, N. (2025). Safety and efficacy of drug-eluting stents improved dramatically with application of nanotechnology. Advanced Journal of Chemistry, Section A, 8(2), 378–391. <https://doi.org/10.48309/ajca.2025.467077.1591>
35. Theivanathan, G., Mohamed Sikkander, A., Hemavathy, N., Murukesh, & Mishra, S. R. (2022). Tactile system for visually impaired people using embedded technology. International Journal of Scientific Research and Innovative Studies, 1(1), 14–19.
36. Sikkander, A. M., RamaNachiar, R., & Yasmeen, K. (2022). Spiking neural network (SNN) using to detect breast cancer. International Journal of Scientific Research and Innovative Studies, 1(1), 20–22.
37. Afzal, O., Altamimi, A. S. A., Nadeem, M. S., Alzarea, S. I., Almalki, W. H., Tariq, A., Mubeen, B., Murtaza, B. N., Iftikhar, S., Riaz, N., & Kazmi, I. (2022). Nanoparticles in drug delivery: From history to therapeutic applications. Nanomaterials, 12(24), 4494. <https://doi.org/10.3390/nano12244494>
38. Abed, A., Mirzaei, S.A., Hosseini, S.A. et al. Metal nanoparticles and sensitivity/resistance to therapy in cancer: two sides of the coin?. J Nanopart Res 27, 44 (2025). <https://doi.org/10.1007/s11051-025-06228-y>
39. Chen, Z., Wang, W., Abdul Razak, S.R. et al. Ferroptosis as a potential target for cancer therapy. Cell Death Dis 14, 460 (2023). <https://doi.org/10.1038/s41419-023-05930-w>

40. Degirmenci, N.S., Yildirim, Z., Padar, G. et al. Combination of sodium pentaborate pentahydrate, curcumin and piperine treatment induces ferroptosis in hepatocellular carcinoma cells by regulating iron homeostasis and ROS activity in vitro. *Med Oncol* 43, 129 (2026). <https://doi.org/10.1007/s12032-025-03223-0>
41. Degirmenci, N.S., Yildirim, Z., Padar, G. et al. Combination of sodium pentaborate pentahydrate, curcumin and piperine treatment induces ferroptosis in hepatocellular carcinoma cells by regulating iron homeostasis and ROS activity in vitro. *Med Oncol* 43, 129 (2026). <https://doi.org/10.1007/s12032-025-03223-0>
42. Madappan, D., Krishnegowda, M.B., Naik, P. et al. Ferroptosis-centered strategies: redefining therapeutic resistance & adaptation in modern oncology. *Apoptosis* 31, 62 (2026). <https://doi.org/10.1007/s10495-026-02279-1>
43. Sikkander, A. M., RamaNachiar, R., & Yasmeen, K. (2022). Artificial neural networks (ANNs) in lung cancer detection. *International Journal of Scientific Research and Innovative Studies*, 1(1), 155–158.
44. Sikk, A. M., & Abbas, H. S. (n.d.). A novel biosensor for pathogens diagnosis. <https://www.alliedacademies.org/articles/a-novel-biosensor-for-pathogens-diagnosis-17372>.
45. Sikkander, A. M., & Yasmeen, K. (2021). Review on nanotechnology: Curative applications in the medicinal field and its adverse effects. *Journal of Science and Technology*, 6(2), 1–8. <https://doi.org/10.46243/jst.2021.v6.i2.pp01-08>
46. Sikkander, M., Vedhi, C., & Manisankar, P. (2014). Enhanced electrochemical sensing of nimodipine with sodium montmorillonite clay. *Moroccan Journal of Chemistry*. <https://doi.org/10.48317/imist.prm/morjchem-v2i4.2135>
47. Sikkander, A. M., Rodrigues, J. J. P. C., Meena, M., & Abuelmakarem, H. S. (2025). AI-powered generative frameworks for the rational design of synthetic genomes and next-generation cellular architectures. *World Journal of Multidisciplinary Studies*, 2(12), 46–53. <https://doi.org/10.65336/wjms.2025.21204>
48. Sikkander, A. M., Rodrigues, J. J. P. C., Meena, M., & Abuelmakarem, H. S. (2025). Leveraging artificial intelligence to integrate genomics, transcriptomics, and proteomics data for enhanced disease prediction. *World Journal of Applied Medical Sciences*, 2(12), 31–39. <https://doi.org/10.65336/wjams.2025.21205>
49. Sikkander, A. M., Rodrigues, J. J. P. C., Meena, M., & Abuelmakarem, H. S. (2025). Trustworthy and transparent AI for genomic discovery. *World Journal of Multidisciplinary Studies*, 2(12), 39–45. <https://doi.org/10.65336/wjms.2025.21203>
50. Sikkander, A. M., Rodrigues, J. J. P. C., Meena, M., & Abuelmakarem, H. S. (2025). Intelligent visualization frameworks driven by AI for multi-dimensional genomic data exploration and interpretation. *World Journal of Multidisciplinary Studies*, 2(12), 31–38. <https://doi.org/10.65336/wjms.2025.21202>
51. Sikkander, A. M., Rodrigues, J. J. P. C., Meena, M., & Abuelmakarem, H. S. (2025). AI-driven genomic biomarker discovery for precision diagnosis and personalized treatment. *World Journal of Applied Medical Sciences*, 2(12), 14–23. <https://doi.org/10.65336/wjams.2025.21203>
52. Sikkander, A. M., Rodrigues, J. J. P. C., Abuelmakarem, H. S., & Meena, M. (2025, November 28). Nanotechnology beneath: Innovations fuelling advances in acute care medicine, cardiology, oncology, and hypertension. <https://waspublication.com/index.php/wjams/article/view/181>
53. de la Lastra, J.M.P., Andrés, C.M.C., Munguira, E.B. et al. Pathophysiology of reactive oxygen species (ROS). *Arch Toxicol* 100, 475–513 (2026). <https://doi.org/10.1007/s00204-025-04276-w>
54. Pan, X., Chen, K., Gao, W. et al. Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer. *Mol Cancer* 24, 29 (2025). <https://doi.org/10.1186/s12943-025-02234-9>
55. Sikkander, A. M., Rodrigues, J. J. P. C., Abuelmakarem, H. S., & Meena, M. (2025, November 26). Biomedical engineering innovations driving breakthroughs in cardiology, oncology, hypertension, and acute care medicine. <https://waspublication.com/index.php/wjams/article/view/180>
56. Sikkander, A. M., Rodrigues, J. J. P. C., Abuelmakarem, H. S., & Meena, M. (2025, November 24). AI beneath: Innovations driving breakthroughs in cardiology, oncology, hypertension, and acute care medicine. <https://waspublication.com/index.php/wjams/article/view/179>
57. Sikkander, A. M., Yadav, C. H., & Revanuri, N. (2025, November 21). Current developments in cyclophosphamide for lymphoma: Immunomodulation, metronomic approaches, and toxicity control. <https://waspublication.com/index.php/wjams/article/view/177>
58. Sikkander, A. M., Yadav, C. H., & Revanuri, N. (2025). A meta-analysis in non-small-cell lung cancer (NSCLC) indicates glucocorticoid administration is significantly associated with worse progression-free survival and overall survival for patients on ICIs. <https://waspublication.com/index.php/wjams/article/view/176>
59. Sikkander, A. R. M., Mishra, S. R., Shankaranarayanan, S., & Chegini, S. (2025). The iPSC-based models for hereditary arrhythmias: From genotype–phenotype studies to precision therapy. *SPC Journal of Medical and Healthcare*, 1(3), 184–191. <https://doi.org/10.48309/sjmh.2025.537906.107>
60. Mohamed Sikkander, A. R., Chegini, S., Mishra, S. R., & Subramanian, S. (2025). Integration of 6G networks and deep learning for advanced biomedical engineering applications: Real-time analytics, remote surgery, and intelligent healthcare systems. *SPC Journal of Medical and Healthcare*, 1(3), 167–175. <https://doi.org/10.48309/sjmh.2025.537895.1073>
61. Sikkander, A. R. M., Lakshmi, V. V., Theivanathan, G., & Radhakrishnan, K. (2024). Multiresolution evaluation of contourlet transform for the diagnosis of skin cancer. *SSR Preprints*. <https://doi.org/10.21203/rs.3.rs-4778827/v1>
62. Sikkander, A. M., Yasmeen, K., & Haseeb, M. (2024). Biological synthesis, characterization, and therapeutic utility

- of Fusarium oxysporum silver nanoparticles. SSR Preprints. <https://doi.org/10.21203/rs.3.rs-4649729/v1>
63. Sikkander, A. M. (2022, October 3). Nanosilicones in sub-glandular and sub-muscular implant breast transplantation. International Journal of Analytical and Applied Chemistry. <https://chemical.journalspub.info/index.php?journal=JAAC&page=article&op=view&path%5B%5D=1309>
  64. Sikkander, A. M. (2022, September 19). Assessment of basal cell carcinoma. International Journal of Chemical and Molecular Engineering. <https://chemical.journalspub.info/index.php?journal=JCME&page=article&op=view&path%5B%5D=1311>
  65. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71:209–49.
  66. Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., Dhanjal, J. K., Dewanjee, S., Vallamkondu, J., & De La Lastra, J. M. P. (2022). Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases, 10(4), 1367–1401. <https://doi.org/10.1016/j.gendis.2022.02.007>
  67. Zafar, A., Khan, M.J., Abu, J. et al. Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. Mol Biol Rep 51, 219 (2024). <https://doi.org/10.1007/s11033-023-09096-8>
  68. Miao, H., Fang, Y., Pan, C., Yang, H., Wang, Z., Qi, Y., Wu, Y., Zhang, Y., Liu, F., Huang, H., Tang, Y., Wu, D., & Li, N. (2025). Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives. Medicine Plus, 2(2), 100087. <https://doi.org/10.1016/j.medp.2025.100087>
  69. Ghemrawi, R., Abuamer, L., Kremesh, S., Hussien, G., Ahmed, R., Mousa, W., Khoder, G., & Khair, M. (2024). Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. Biomedicines, 12(9), 2158. <https://doi.org/10.3390/biomedicines12092158>
  70. Maqbool, H., Yasin, U., Shawal, L., Zulfikar, F., Fatima, N., Hasan, W., Nasim, H., Ismail, M., & Rafiq, M. (2024). ADVANCEMENTS IN CANCER PHARMACOTHERAPY: TARGETED THERAPIES AND IMMUNOTHERAPY STRATEGIES, a REVIEW. Biological and Clinical Sciences Research Journal, 2024(1), 1025. <https://doi.org/10.54112/bcsrj.v2024i1.1025>
  71. Sikkander, A. M. (2022, September 17). Nanoemulsion in ophthalmology. International Journal of Chem-Informatics Research. <https://chemical.journalspub.info/index.php?journal=JAWCM&page=article&op=view&path%5B%5D=1310>
  72. Sikkander, M., & Abbas, H. S. (2021). Biosensors for pathogens diagnosis. Journal of Chemical Technology Applications, 2(2), 1–3. <https://www.alliedacademies.org/articles/biosensors-for-pathogens-diagnosis.pdf>
  73. Sikk, M., Er, A., & Yasmeen, K. (n.d.). Evaluation of surgical risk in patients with liver cancer. <https://doi.org/10.35841/aaccr-5.3.115>
  74. Sikkander, A. M., Yadav, C. H., & Revanuri, N. (2025). Recent trends in Oncovin (vincristine) use for acute lymphoblastic leukemia: Liposomal formulations, pharmacogenomics, and toxicity-mitigation strategies. ISAR Journal of Medical and Pharmaceutical Sciences, 3(11), 20–23.
  75. Sikkander, A. R. M., & Rodrigues, J. J. P. C. (2026, January 28). Machine learning models to predict chemotherapy resistance in breast cancer using single-cell sequencing. <https://waspublication.com/index.php/wjams/article/view/219>
  76. Sikkander, A. R. M., & Rodrigues, J. J. P. C. (2026, January 27). Deep-learning models for ultrasound, mammography, and MRI fusion for accurate tumor segmentation. <https://waspublication.com/index.php/wjams/article/view/218>
  77. Sikkander, A. M., Yadav, C. H., & Revanuri, N. (2025). Current trends: Recent innovations and impacts of flap necrosis in breast reduction. ISAR Journal of Medical and Pharmaceutical Sciences, 3(11), 12–19.
  78. Razak, M. S. A., Lakshmi, V. V., & Rodrigues, J. J. P. C. (2025). Multiresolution analysis of wavelets using artificial intelligence for skin cancer detection. SSRN Electronic Journal. <https://doi.org/10.2139/ssrn.5142172>
  79. Razak, M. S. A., Lakshmi, V. V., Theivanathan, G., & Radhakrishnan, K. (2025). Artificial intelligence-driven multidirectional curvelet analysis for enhanced skin cancer detection. SSRN Electronic Journal. <https://doi.org/10.2139/ssrn.5127060>
  80. Gupta, J. K., Sikkander, A. R. M., Nagrami, F. U. H., Kumar, K., & Wahi, N. (2023). Appraisal, recent advancement, and impacts of nanomedicine in cardiac asthma. Journal of Medical Pharmaceutical and Allied Sciences, 12(5), 6132–6138. <https://doi.org/10.55522/jmpas.v12i5.5214>
  81. Carneiro, B.A., El-Deiry, W.S. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol 17, 395–417 (2020). <https://doi.org/10.1038/s41571-020-0341-y>
  82. Indran, I. R., Tufo, G., Pervaiz, S., & Brenner, C. (2011). Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochimica Et Biophysica Acta (BBA) - Bioenergetics, 1807(6), 735–745. <https://doi.org/10.1016/j.bbabi.2011.03.010>
  83. Hu, W., & Kavanagh, J. J. (2003). Anticancer therapy targeting the apoptotic pathway. The Lancet Oncology, 4(12), 721–729. [https://doi.org/10.1016/s1470-2045\(03\)01277-4](https://doi.org/10.1016/s1470-2045(03)01277-4)
  84. Singh, V., Khurana, A., Navik, U., Allawadhi, P., Bharani, K. K., & Weiskirchen, R. (2022). Apoptosis and Pharmacological Therapies for Targeting Thereof for Cancer Therapeutics. Sci, 4(2), 15. <https://doi.org/10.3390/sci4020015>
  85. Zhang, X., Xiang, Y., Wang, Q., Bai, X., Meng, D., Wu, J., Sun, K., Zhang, L., Qiang, R., Liu, W., Zhang, X., Qiang, J., Liu, X., & Yang, Y. (2025). Regulation of iron metabolism in ferroptosis: From mechanism research to clinical translation.

- Journal of Pharmaceutical Analysis, 15(10), 101304. <https://doi.org/10.1016/j.jpha.2025.101304>
86. Yadav, C. H., Revanuri, N., & Mohamed Sikkander, A. R. (2025). Organometallic compound phototoxicity against cancer cells. *Biomedical Engineering: Applications, Basis and Communications*. <https://doi.org/10.4015/S1016237225500206>
87. Sikkander, A. M., Ranjan, R., & Mishra, S. R. (2024). Artificial intelligence in cerebellum activation. *International Journal of Cheminformatics*, 1(1), 14–26. <https://journals.stmjournals.com/ijci/article=2024/view=143947>
88. Mohamed Sikkander, A. R., Ranjan, R., & Mishra, S. R. (2024). Nanoelectronics, nanoparticles, and nanotechnology in treatment of psychological disorders. *International Journal of Environmental Chemistry*. <https://journals.stmjournals.com/ijec/article=2024/view=143513>
89. Sikkander, A. M., Ranjan, R., & Sikkander, A. M. (2024). Organometallic osmium compounds in cancer therapy. *International Journal of Advance in Molecular Engineering*, 1(2), 1–25. <https://journals.stmjournals.com/ijame/article=2024/view=144940>
90. Mohamed Sikkander, A. R. (2024). Catalytic activity advancements in organometallic chemistry. <https://engineeringjournals.stmjournals.in/index.php/JoCC/issue/view/1274>
91. Shen, G., Liu, J., Wang, Y., Deng, Z., & Deng, F. (2025). Ferroptosis in Cancer and Inflammatory Diseases: Mechanisms and therapeutic implications. *MedComm*, 6(9), e70349. <https://doi.org/10.1002/mco2.70349>
92. Jin, X., Tang, J., Qiu, X. et al. Ferroptosis: Emerging mechanisms, biological function, and therapeutic potential in cancer and inflammation. *Cell Death Discov*. 10, 45 (2024). <https://doi.org/10.1038/s41420-024-01825-7>
93. Wang, J., Guo, D., Jiang, S. et al. Targeting ferroptosis in cancer: from mechanistic insights to therapeutic approaches. *Mol Biomed* 7, 20 (2026). <https://doi.org/10.1186/s43556-026-00416-5>
94. Asiedu, R.K.F., Souley Abdou, M., Wei, R. et al. Harnessing pyroptosis in breast cancer therapy: immunological mechanisms and emerging biomaterial strategies. *Cell Death Discov*. (2026). <https://doi.org/10.1038/s41420-026-02996-1>
95. Gupta, J. K., Sikkander, A. R. M., Nagrami, F. U. H., Kumar, K., & Wahi, N. (2023). Appraisal, recent advancement, and impacts of nanomedicine in cardiac asthma. *Journal of Medical Pharmaceutical and Allied Sciences*, 12(5), 6132–6138. <https://doi.org/10.55522/jmpas.v12i5.5214>
96. Sikkander, A. M. (2022). Nanosilicones in sub-glandular and sub-muscular implant breast transplantation. *International Journal of Analytical and Applied Chemistry*. <https://chemical.journalspub.info/index.php?journal=JAAC&page=index>
97. Sikkander, A. M. (2022). Assessment of basal cell carcinoma. *International Journal of Chemical and Molecular Engineering*, 8(2). <https://chemical.journalspub.info/index.php?journal=JCME&page=issue&op=view&path%5B%5D=273>
98. Imtiaz, S., Ferdous, U. T., Nizela, A., Hasan, A., Shakoor, A., Zia, A. W., & Uddin, S. (2025). Mechanistic study of cancer drug delivery: Current techniques, limitations, and future prospects. *European Journal of Medicinal Chemistry*, 290, 117535. <https://doi.org/10.1016/j.ejmech.2025.117535>
99. Sikkander, A. M. (2022). Nanoemulsion in ophthalmology. *International Journal of Chem-Informatics Research*, 8(2). <https://chemical.journalspub.info/index.php?journal=JAWCM&page=index>
100. Sikkander, A. M. (2023). Advancement of agricultural biotechnology in USA. *International Journal of AgroChemistry*, 9(2). <https://chemical.journalspub.info/index.php?journal=IJCPD&page=index>
101. Ko, M. J., Min, S., Hong, H., Yoo, W., Joo, J., Zhang, Y. S., Kang, H., & Kim, D. (2023). Magnetic nanoparticles for ferroptosis cancer therapy with diagnostic imaging. *Bioactive Materials*, 32, 66–97. <https://doi.org/10.1016/j.bioactmat.2023.09.015>
102. Wei, Y., Han, B., Hu, X., Lin, Y., Wang, X., & Deng, X. (2012). Synthesis of Fe<sub>3</sub>O<sub>4</sub> Nanoparticles and their Magnetic Properties. *Procedia Engineering*, 27, 632–637. <https://doi.org/10.1016/j.proeng.2011.12.498>
103. Van Acker, T., Theiner, S., Bolea-Fernandez, E. et al. Inductively coupled plasma mass spectrometry. *Nat Rev Methods Primers* 3, 52 (2023). <https://doi.org/10.1038/s43586-023-00235-w>
104. Huang, B., Wang, H., Liu, S. et al. Palmitoylation-dependent regulation of GPX4 suppresses ferroptosis. *Nat Commun* 16, 867 (2025). <https://doi.org/10.1038/s41467-025-56344-5>
105. Bai, JW., Qiu, SQ. & Zhang, GJ. Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. *Sig Transduct Target Ther* 8, 89 (2023). <https://doi.org/10.1038/s41392-023-01366-y>
106. Malm, A.V., Corbett, J.C.W. Improved Dynamic Light Scattering using an adaptive and statistically driven time resolved treatment of correlation data. *Sci Rep* 9, 13519 (2019). <https://doi.org/10.1038/s41598-019-50077-4>
107. Monteleone, M., Stanley, A. C., Chen, K. W., Brown, D. L., Bezbradica, J. S., Von Pein, J. B., Holley, C. L., Boucher, D., Shakespear, M. R., Kapetanovic, R., Rolfes, V., Sweet, M. J., Stow, J. L., & Schroder, K. (2018). Interleukin-1 $\beta$  Maturation Triggers Its Relocation to the Plasma Membrane for Gasdermin-D-Dependent and -Independent Secretion. *Cell Reports*, 24(6), 1425–1433. <https://doi.org/10.1016/j.celrep.2018.07.027>
108. Archetti, C., Peirano, L., & Speranza, M. G. (2021c). Optimization in multimodal freight transportation problems: A Survey. *European Journal of Operational Research*, 299(1), 1–20. <https://doi.org/10.1016/j.ejor.2021.07.031>
109. O'Melia, M. J., Rohner, N. A., Manspeaker, M. P., Francis, D. M., Kissick, H. T., & Thomas, S. N. (2020). Quality of CD8 + T cell immunity evoked in lymph nodes is compartmentalized

- by route of antigen transport and functional in tumor context. *Science Advances*, 6(50). <https://doi.org/10.1126/sciadv.abd7134>
110. Li, X., Peng, X., Zoulikha, M. et al. Multifunctional nanoparticle-mediated combining therapy for human diseases. *Sig Transduct Target Ther* 9, 1 (2024). <https://doi.org/10.1038/s41392-023-01668-1>
111. Adzavon, K. P., Zhao, W., He, X., & Sheng, W. (2024b). Ferroptosis resistance in cancer cells: nanoparticles for combination therapy as a solution. *Frontiers in Pharmacology*, 15, 1416382. <https://doi.org/10.3389/fphar.2024.1416382>
112. Passaro, A., Bakir, M. A., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mounzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024). Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. *Cell*, 187(7), 1617–1635. <https://doi.org/10.1016/j.cell.2024.02.041>
113. Goswami, S., Pauken, K.E., Wang, L. et al. Next-generation combination approaches for immune checkpoint therapy. *Nat Immunol* 25, 2186–2199 (2024). <https://doi.org/10.1038/s41590-024-02015-4>
114. Bae, H., Ji, H., Konstantinov, K., Sluyter, R., Ariga, K., Kim, Y. H., & Kim, J. H. (2025). Artificial Intelligence-Driven Nanoarchitectonics for smart targeted drug delivery. *Advanced Materials*, 37(42), e10239. <https://doi.org/10.1002/adma.202510239>
115. Hosseini, S., Mohammadnejad, J., Salamat, S., Zadeh, Z. B., Tanhaei, M., & Ramakrishna, S. (2023). Theranostic polymeric nanoparticles as a new approach in cancer therapy and diagnosis: a review. *Materials Today Chemistry*, 29, 101400. <https://doi.org/10.1016/j.mtchem.2023.101400>
116. Li, Y., Pan, X., Hai, P., Zheng, Y., Shan, Y., & Zhang, J. (2024). All-in-one nanotheranostic platform based on tumor microenvironment: new strategies in multimodal imaging and therapeutic protocol. *Drug Discovery Today*, 29(7), 104029. <https://doi.org/10.1016/j.drudis.2024.104029>
117. Pan, Y., Xue, X., & Liang, X. (2024). Nanotechnology-Empowered Combination Cancer Immunotherapies: Mechanisms, synergies, and perspectives. *Advanced NanoBiomed Research*, 4(4). <https://doi.org/10.1002/anbr.202300129>
118. Lei, W., Zhou, K., Lei, Y. et al. Cancer vaccines: platforms and current progress. *Mol Biomed* 6, 3 (2025). <https://doi.org/10.1186/s43556-024-00241-8>
119. Lei, W., Zhou, K., Lei, Y. et al. Cancer vaccines: platforms and current progress. *Mol Biomed* 6, 3 (2025). <https://doi.org/10.1186/s43556-024-00241-8>
120. Gu, Y., Yang, R., Zhang, Y. et al. Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. *Mol Biomed* 6, 2 (2025). <https://doi.org/10.1186/s43556-024-00239-2>
121. Crucitta, S., Cucchiara, F., Mathijssen, R., Mateo, J., Jager, A., Joosse, A., Passaro, A., Attili, I., Petrini, I., Van Schaik, R., Danesi, R., & Del Re, M. (2022). Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. *Cancer Treatment Reviews*, 104, 102340. <https://doi.org/10.1016/j.ctrv.2022.102340>
122. Youssef, E., Fletcher, B., & Palmer, D. (2025). Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology. *Frontiers in Medicine*, 11, 1527600. <https://doi.org/10.3389/fmed.2024.1527600>
123. Nussinov, R., Weichhart, T., Dlamini, Z., Gibbons, D. L., Van Seuning, I., Konen, J., & Ju, H. (2024). Directions to overcome therapy resistance in cancer. *Trends in Pharmacological Sciences*, 45(6), 467–471. <https://doi.org/10.1016/j.tips.2024.05.001>